(Q37118201)

18 August 2017

1 reference

title

Twelve immunotherapy drugs that could cure cancers (English)

1 reference

18 August 2017

1 reference

Martin A Cheever

1

1 reference

18 August 2017

1 April 2008

1 reference

18 August 2017

Immunological Reviews

1 reference

18 August 2017

222

1 reference

18 August 2017

357-368

1 reference

Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders

18 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Allogeneic hematopoietic cell transplantation as immunotherapy for solid tumors: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Cancer vaccines: between the idea and the reality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Effector memory T cells, early metastasis, and survival in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Human tumor-specific T lymphocytes: does function matter more than number?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Cancer immunotherapy: breaking the barriers to harvest the crop

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Interleukin-7: master regulator of peripheral T-cell homeostasis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

IL-7 administration alters the CD4:CD8 ratio, increases T cell numbers, and increases T cell function in the absence of activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Interleukin-7 improves CD4 T-cell reconstitution after autologous CD34 cell transplantation in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Restoring function in exhausted CD8 T cells during chronic viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Help for cytotoxic-T-cell responses is mediated by CD40 signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Triggering CD40 on endothelial cells contributes to tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

The TRAIL to selective tumor death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

CD40 AND CD154 IN CELL-MEDIATED IMMUNITY

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Prospect of targeting the CD40 pathway for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Anti-CD40 agonist antibodies: preclinical and clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Indoleamine 2,3-dioxygenase and tumor-induced tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Indoleamine 2,3-dioxygenase in immune suppression and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Cutting edge: Expression of functional CD137 receptor by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Induction of potent antitumor immunity by in situ targeting of intratumoral DCs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Differential tumor surveillance by natural killer (NK) and NKT cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Antitumor and antimetastatic activity of interleukin 12 against murine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Effect of interleukin 12 on tumor induction by 3-methylcholanthrene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Interleukin-12 in anti-tumor immunity and immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Inhibition of angiogenesis in vivo by interleukin 12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Therapeutic potential of Toll-like receptor 9 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Development of TLR9 agonists for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Safety evaluation of monophosphoryl lipid A (MPL): an immunostimulatory adjuvant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Crystal structure of human toll-like receptor 3 (TLR3) ectodomain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Innate immune recognition of viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Toll-like receptors and Type I interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Topical immunomodulators--progress towards treating inflammation, infection, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Cooperation of Toll-like receptor signals in innate immune defence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Toll-like receptor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00604.X

10.1111/J.1600-065X.2008.00604.X

21 January 2018

Identifiers

DOI

1 reference

release_4szleomg7vcezbo75rbdgk3zra

18 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4szleomg7vcezbo75rbdgk3zra

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

18364014

1 reference

PubMed ID

18364014